Where Will Vaxart Be in 1 Year?
Vaxart (NASDAQ: VXRT) is one of the most dynamic coronavirus vaccine stocks of the year so far, with its share price growing from less than a dollar in January to nearly $17 in mid-July. While Vaxart has since fallen to around $7 as its speculation-induced bubble continues to deflate, the company's long-term prospects are still favorable thanks to its unique oral vaccine platform. In fact, Vaxart's platform won a critical validation earlier this year, when the company's influenza vaccine demonstrated superior efficacy to Sanofi's (NASDAQ: SNY) Fluzone in a direct comparison.
With this promising flu vaccine advancing to phase 3 of clinical trials, its coronavirus candidate entering phase 1, and a looming class action lawsuit from shareholders, there's a lot coming up in the next 12 months for Vaxart's. Let's take a closer look to get a better idea about whether the stock warrants a place in your biotech portfolio.
Image source: Getty Images.
Source Fool.com
